Stay updated with breaking news from Nasdaq Aplm. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Apollomics (NASDAQ:APLM – Free Report) had its target price lowered by HC Wainwright from $17.00 to $5.00 in a report issued on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Apollomics’ Q1 2024 earnings at ($0.17) EPS, Q2 2024 earnings at ($0.18) EPS, […]
FOSTER CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company...
FOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company...
Apollomics (NASDAQ:APLM – Get Free Report) had its target price reduced by stock analysts at HC Wainwright from $18.00 to $17.00 in a report released on Tuesday, MarketBeat reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 431.25% from the company’s previous close. […]
Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation expected second half...